注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Immunome Inc是一家生物製藥公司,利用其人類記憶B細胞平台來發現和開發抗體療法。該公司的主要重點領域是腫瘤學和傳染病。其發現平台通過利用免疫系統的組成部分記憶B細胞識別治療性抗體及其靶點,記憶B細胞來自已經學會對抗疾病的患者。其先導發現項目包括IMM-ONC-01和IMM-BCP-01。該公司的IMM-ONC-01是其主要的腫瘤學項目,專注於白細胞介素38(IL-38),這是一種能夠促進免疫系統逃避的腫瘤衍生免疫檢查點。IMM-BCP-01是其主要的傳染病發現項目,重點關注導致COVID-19的病毒SARS-CoV-2。該公司正在開發一種抗體混合候選產品,方法是確定由COVID-19超級反應者的B細胞產生的抗病毒抗體組合。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Philip Wagenheim | 53 | 2017 | Director |
George C. Prendergast | - | - | Member of Scientific Advisory Board |
Shmuel Shoham | - | 2020 | Member of COVID-19 Advisory Board |
Louis M. Weiner | 72 | - | Member of Scientific Advisory Board |
John M. Lambert | 73 | 2023 | Member of Antibody-Drug Conjugate & T Cell Redirection Advisory Board |
Isaac Barchas | 57 | 2023 | Lead Independent Director |
Jeffrey Henderson | - | 2020 | Member of COVID-19 Advisory Board |
Susan Weiss | - | 2020 | Member of COVID-19 Advisory Board |
Andrew D. Badley | - | 2021 | Member of COVID-19 Advisory Board |
William Strohl | 71 | - | Member of Scientific Advisory Board |
Anthony W. Tolcher | - | - | Member of Scientific Advisory Board and Member of ADC & T Cell Redirection Advisory Board |
Clay B. Siegall | 63 | 2023 | President, CEO & Chairman |
James Patrick Boylan | 56 | 2023 | Independent Director |
Carol A. Schafer | 60 | 2024 | Independent Director |
Sandra M. Swain | 69 | 2024 | Independent Director |
Jean-Jacques Bienaime | 71 | 2023 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核